Baxter's Norepinephrine Wins FDA Nod For Low Blood Pressure

by Vandana Singh, Benzinga Editor

September 23, 2021 11:24 AM | 1 min read |

The FDA has approved Baxter International Inc's BAX premix norepinephrine bitartrate in 5% dextrose injection.
Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).
According to a news release, the company's formulation of norepinephrine is the first and only manufacturer-prepared, ready-to-use formulation.
The Company offers the formulation in 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) strengths.
Baxter's formulation has a shelf life of up to 21 months in a refrigerator or up to 90 days at room temperature in overwrap. It can be stored in automated dispensing cabinets at the point of care.
Related content: Benzinga's Full FDA Calendar.
Price Action: BAX stock is up 0.12% at $81.15 during the market session on the last check Thursday.

Posted In: News Health Care FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.